---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-026339"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:40:31.675099+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Esperion Q2 U.S. product revenue +49% to $20.3M; net loss narrows to $49.9M

## Summary
- Total revenue $25.8M (+37% YoY); U.S. net product revenue $20.3M (+49% YoY) driven by 26% retail Rx growth.
- Net loss $49.9M ($0.46 per share) versus $66.3M ($1.05) in Q2 2022; R&D expenses fell 32% to $22.1M.
- Submitted FDA sNDAs and EMA application to expand NEXLETOL/NEXLIZET labels; approvals expected 1H 2024.
- Presented CLEAR Outcomes primary prevention analysis at ADA, published in JAMA, expanding addressable U.S. market to 70M patients.
- Cash and investments $138.5M as of June 30, 2023; full-year 2023 opex outlook reaffirmed at $225-245M.

## SEC filing metadata
- accession: 0001628280-23-026339
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/0001628280-23-026339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/espr-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-026339
- JSON: https://secwatch.observer/filing/0001628280-23-026339.json
- Plain text: https://secwatch.observer/filing/0001628280-23-026339.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $25.8 million, net income $49.9 million, EPS $0.46.
  - Period: second quarter ended June 30, 2023
  - Revenue: $25.8 million
  - Net income: $49.9 million
  - EPS: $0.46
  - Result: reported results
  source text: Outcomes Analysis by Glycaemic Status, presented by Kausik K Ray. Second Quarter and YTD 2023 Financial Results Total revenue for the second quarter ended June 30, 2023, was $25.8 million and $50.1 million for the six months ended June 30, 2023, compared to $18.8 million and $37.7 million for the comparable periods in 2022, an increase of 37% and 33%,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/0001628280-23-026339-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.